"
Q95 - Continuous Renal Replacement Therapy (CRRT) in ICU — Modalities, Dose & Anticoagulation
Q95 · Paper II · 10 MARKS · Long Answer
Continuous Renal Replacement Therapy (CRRT) in ICU — Modalities, Dose & Anticoagulation
Question: Compare and contrast intermittent haemodialysis (IHD) with continuous renal replacement therapy (CRRT) modalities – CVVH, CVVHD, and CVVHDF [4]. Discuss the prescribed dose of CRRT, anticoagulation strategies (heparin vs citrate), and timing of initiation in AKI [4]. Outline specific indications for CRRT beyond AKI and describe circuit troubleshooting [2].
Core ConceptCRRT is preferred in haemodynamically unstable critically ill patients – slow continuous removal avoids the rapid shifts of IHD. Dose should be 20–25 mL/kg/hr; higher confers no benefit (RENAL/ATN trials).
A. IHD vs CRRT Modalities4 marks
| Feature | IHD | CVVH | CVVHD | CVVHDF |
|---|
| Mechanism | Diffusion | Convection | Diffusion | Both |
| Haemodynamic stability | Poor | Excellent | Excellent | Excellent |
| ICP effect | Unfavourable (disequilibrium) | Favourable | Favourable | Favourable |
| Preferred in | Stable/chronic RF | Unstable ICU, raised ICP | High diffusive need | Most critically ill |
B. Dose, Anticoagulation & Timing4 marks
- Dose: prescribe 25–30 mL/kg/hr to deliver ~20–25 (RENAL & ATN trials: no mortality benefit above this).
- Citrate anticoagulation (preferred, KDIGO): chelates ionised Ca²⁺ in circuit; superior filter life, less bleeding than heparin; CI in severe liver failure (citrate accumulation).
- Heparin: cheap, reversible, but systemic bleeding/HIT risk.
- Timing (STARRT-AKI 2020): accelerated vs standard initiation – no mortality difference; avoid over-starting (impairs renal recovery). Absolute indications: refractory K⁺>6.5, pH<7.15, refractory pulmonary oedema, uraemic complications.
C. Non-AKI Indications & Troubleshooting2 marks
- Non-AKI: refractory fluid overload, cytokine removal in sepsis (limited evidence), acute liver failure (MARS), rhabdomyolysis (myoglobin clearance), drug overdose (lithium, salicylates, metformin).
- Troubleshooting: access pressure alarm → kinked catheter; high TMP → filter clotting; blood leak → membrane breach; citrate accumulation → total:ionised Ca ratio >2.5 → reduce citrate.
Examiner's PearlCVVH=convection; CVVHD=diffusion; CVVHDF=both. CRRT preferred: unstable, raised ICP, liver failure. Dose 20–25 mL/kg/hr delivered (RENAL/ATN: no benefit above this). Citrate preferred (KDIGO) except severe liver failure. STARRT-AKI: no mortality benefit to early initiation.
References: Bellomo R et al. NEJM 2009;361:1627-1638. VA/NIH ATN study. NEJM 2008;359:7-20. KDIGO AKI Guideline 2012. STARRT-AKI. NEJM 2020;383:240-251.
"